Latest news newssearch boxGO All Ad hoc Other 02 May 2022 Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia 26 Apr 2022 Idorsia gibt Finanzergebnisse für das erste Quartal 2022 bekannt – Erstes Produkt eingeführt, zweites Produkt in den Startlöchern 20 Apr 2022 PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan 14 Apr 2022 Idorsia hält ordentliche Generalversammlung ab 04 Apr 2022 The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage 10 Mar 2022 New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022 03 Mar 2022 Idorsia veröffentlicht Ankündigung der ordentlichen Generalversammlung 2022 25 Feb 2022 QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder 08 Feb 2022 Idorsia gibt Finanzergebnisse für 2021 bekannt – 2022 wird ein Jahr der Transformation – Nachhaltige Rentabilität soll 2025 erreicht werden 26 Jan 2022 Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada 24 Jan 2022 Idorsia ernennt Guy Braunstein zum Chief Medical Officer und Alberto Gimona zum Head of Global Clinical Development 20 Jan 2022 Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg 20 Jan 2022 The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia 12 Jan 2022 Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep 10 Jan 2022 Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA 10 Jan 2022 Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia 13 Dec 2021 Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study 01 Nov 2021 Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus 27 Oct 2021 Johnson & Johnson partially converts its convertible loan 26 Oct 2021 Idorsia publiziert die Finanzergebnisse für das dritte Quartal 2021 – Das Unternehmen kommt weiter voran; Einführungsvorbereitungen für Schlüsselmärkte auf gutem Weg 1 2 3 4 5 6 7
